Patient, donor, and transplant characteristics
. | Values . |
|---|---|
| No. patients | 103 |
| Sex, no. (%) | |
| Female | 49 (47.6) |
| Male | 54 (52.4) |
| Median age, y (range) | 51.8 (18.5-68.2) |
| Diagnosis, no. (%) | |
| De novo AML | 76 (73.8) |
| AML secondary to MDS | 21 (20.4) |
| AML secondary to other malignancies | 6 (5.8) |
| Cytogenetic subgroups, no. (%)* | |
| Good | 5 (4.9) |
| Intermediate | 49 (47.6) |
| Poor | 47 (45.6) |
| Unknown | 2 (1.9) |
| Stage at transplantation, no. (%) | |
| Primary induction failure (PIF)† | 37 (35.9) |
| Relapse after CR1 < 6 mo (ER) | 53 (51.5) |
| Untreated/Ld AraC, no. | 29 |
| In aplasia, no. | 3 |
| Refractory,‡ no. | 20 |
| In CR2, no. | 1 |
| Refractory relapse after > 6 mo in CR,‡ no. (%) | 8 (7.8) |
| 2nd relapse | 5 (4.8) |
| Untreated, no. | 4 |
| Refractory, no. | 1 |
| Median marrow blasts, % (range) | 30 (0-90) |
| Extramedullary disease | |
| Total, no. (%) | 11 (10.6) |
| Present from time of diagnosis, no. | 4 |
| Present only from time of first relapse, no. | 7 |
| Skin, no. | 1 |
| Soft tissue, no. | 3 |
| Meningosis alone, no. | 5 |
| Meningosis + other site, no. | 2 |
| Prior autologous transplantation, no. (%) | |
| Yes | 10 (9.6) |
| No | 93 (90.4) |
| No. of chemotherapy cycles before HCT§, no. (%) | |
| 2 cycles | 36 (35) |
| 3 cycles | 24 (23.3) |
| 4 cycles | 15 (14.6) |
| More than 4 cycles | 28 (27.2) |
| Median (range) | 3 (2-9) |
| Charlson Comorbidity Index score, no. (%) | |
| 0 | 42 (40.8) |
| 1 | 38 (36.8) |
| 2 | 13 (12.6) |
| 3 | 3 (2.9) |
| Greater than 3 | 3 (2.9) |
| NE | 4 (3.9) |
| Median time from diagnosis to transplantation, | |
| d (range) | 215 (73-1187) |
| Donor type, no. (%) | |
| Fully matched family donor | 39 (37.9) |
| Partially matched family donor | 2 (1.9) |
| Fully matched unrelated donor | 49 (47.6) |
| Partially matched unrelated donor | 13 (12.6) |
| Donor sex match, no. (%) | |
| Match | 59 (57.5) |
| Patient male/donor female | 9 (8.7) |
| Patient female/donor male | 24 (23.3) |
| NE | 11 (10.7) |
| CMV status, no. (%) | |
| Patient-/donor- | 21 (20.4) |
| Patient+/donor- | 34 (33.0) |
| Patient-/donor+ | 10 (9.7) |
| Patient+/donor+ | 31 (30.1) |
| NE | 7 (6.8) |
| Stem cell source, no. (%) | |
| Mobilized PBSCs | 93 (90.3) |
| Bone marrow | 10 (9.7) |
| Median no. CD34+ cells within the graft,∥× 106/kg (range) | 8.2 (2.2-23) |
. | Values . |
|---|---|
| No. patients | 103 |
| Sex, no. (%) | |
| Female | 49 (47.6) |
| Male | 54 (52.4) |
| Median age, y (range) | 51.8 (18.5-68.2) |
| Diagnosis, no. (%) | |
| De novo AML | 76 (73.8) |
| AML secondary to MDS | 21 (20.4) |
| AML secondary to other malignancies | 6 (5.8) |
| Cytogenetic subgroups, no. (%)* | |
| Good | 5 (4.9) |
| Intermediate | 49 (47.6) |
| Poor | 47 (45.6) |
| Unknown | 2 (1.9) |
| Stage at transplantation, no. (%) | |
| Primary induction failure (PIF)† | 37 (35.9) |
| Relapse after CR1 < 6 mo (ER) | 53 (51.5) |
| Untreated/Ld AraC, no. | 29 |
| In aplasia, no. | 3 |
| Refractory,‡ no. | 20 |
| In CR2, no. | 1 |
| Refractory relapse after > 6 mo in CR,‡ no. (%) | 8 (7.8) |
| 2nd relapse | 5 (4.8) |
| Untreated, no. | 4 |
| Refractory, no. | 1 |
| Median marrow blasts, % (range) | 30 (0-90) |
| Extramedullary disease | |
| Total, no. (%) | 11 (10.6) |
| Present from time of diagnosis, no. | 4 |
| Present only from time of first relapse, no. | 7 |
| Skin, no. | 1 |
| Soft tissue, no. | 3 |
| Meningosis alone, no. | 5 |
| Meningosis + other site, no. | 2 |
| Prior autologous transplantation, no. (%) | |
| Yes | 10 (9.6) |
| No | 93 (90.4) |
| No. of chemotherapy cycles before HCT§, no. (%) | |
| 2 cycles | 36 (35) |
| 3 cycles | 24 (23.3) |
| 4 cycles | 15 (14.6) |
| More than 4 cycles | 28 (27.2) |
| Median (range) | 3 (2-9) |
| Charlson Comorbidity Index score, no. (%) | |
| 0 | 42 (40.8) |
| 1 | 38 (36.8) |
| 2 | 13 (12.6) |
| 3 | 3 (2.9) |
| Greater than 3 | 3 (2.9) |
| NE | 4 (3.9) |
| Median time from diagnosis to transplantation, | |
| d (range) | 215 (73-1187) |
| Donor type, no. (%) | |
| Fully matched family donor | 39 (37.9) |
| Partially matched family donor | 2 (1.9) |
| Fully matched unrelated donor | 49 (47.6) |
| Partially matched unrelated donor | 13 (12.6) |
| Donor sex match, no. (%) | |
| Match | 59 (57.5) |
| Patient male/donor female | 9 (8.7) |
| Patient female/donor male | 24 (23.3) |
| NE | 11 (10.7) |
| CMV status, no. (%) | |
| Patient-/donor- | 21 (20.4) |
| Patient+/donor- | 34 (33.0) |
| Patient-/donor+ | 10 (9.7) |
| Patient+/donor+ | 31 (30.1) |
| NE | 7 (6.8) |
| Stem cell source, no. (%) | |
| Mobilized PBSCs | 93 (90.3) |
| Bone marrow | 10 (9.7) |
| Median no. CD34+ cells within the graft,∥× 106/kg (range) | 8.2 (2.2-23) |
Ld indicates low dose; HCT, hematopoietic cell transplantation; NE, not evaluable.
According to the SWOG/ECOG criteria.34
As defined by persistent leukemia after at least 2 courses of induction chemotherapy.
As defined by persistent leukemia after at least 1 course of combination chemotherapy containing high-dose AraC for reinduction.
Myeloablative conditioning for autologous SCT was counted as 1 cycle.
Analysis restricted to PBSC transplantations.